Effects of long-term and low-dose hormone replacement therapy on bone mineral density in postmenopausal women

Acta Academiae Medicinae Sinicae

Volumn 28, Issue 3, 2006, Pages 421-424

  Nie, Min ^a   Sun, Mei Li ^a   Ge, Qin Sheng ^a,b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Bone mineral density; Hormone replacement therapy; Low dose; Menopause

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL VALERATE; MEDROXYPROGESTERONE ACETATE; TIBOLONE;

ARTICLE; BONE DENSITY; BONE PAIN; CHINA; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HIP; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LONG TERM CARE; LOW DRUG DOSE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL STAFF; MENOPAUSAL SYNDROME; OSTEOLYSIS; PATIENT SELECTION; TREATMENT DURATION; UNIVERSITY HOSPITAL;

BONE DENSITY; DENSITOMETRY, X-RAY; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTERONE;

EID: 33746147104     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288(3):321-333.
2. Chinese source. 2002, 24(5):245-246.
3. Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in acetate on bone in early postmenopausal women. JAMA, 2002, 287(20):2668-2676.
4. Delmas PD, Confavreux E, Garnero P, et al. A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporosis Int, 2000, 11(2):177-187.
5. Lees B, Stevenson JC. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. Osteopotos Int, 2001, 12(4): 251-258.
6. Gambacciani M, Ciaponi M, Cappagli B, et al. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gynecol Endocrinol, 2004, 18(1):9-16.
7. George GH, MacGregor AJ, Spector TD. Influence of current and past hormone replacement therapy on bone mineral density: a study of discordant postmenopausal twins. Osteoporos Int, 1999, 9(2):158-162.
8. Barrett-Connor E, Wehren LE, Siris ES, et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause, 2003, 10(5): 412-419.
9. Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric, 2002, 5(4):390-398.
10. Eiken P, Nielsen SP, Kolthoff N. Effects on bone mass after eight years of hormonal replacement therapy. Br J Obstet Gynaecol, 1997, 104(6):702-707.